| Market Cap | 250.83M | P/E | - | EPS this Y | 31.00% | Ern Qtrly Grth | - |
| Income | -93.24M | Forward P/E | -4.00 | EPS next Y | -6.00% | 50D Avg Chg | -10.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -22.00% |
| Dividend | N/A | Price/Book | 2.16 | EPS next 5Y | - | 52W High Chg | -45.00% |
| Recommedations | 1.60 | Quick Ratio | 21.67 | Shares Outstanding | 56.43M | 52W Low Chg | 113.00% |
| Insider Own | 0.47% | ROA | -20.04% | Shares Float | 34.22M | Beta | 0.72 |
| Inst Own | 98.95% | ROE | -34.06% | Shares Shorted/Prior | 3.82M/3.95M | Price | 8.95 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 256,843 | Target Price | 25.14 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 217,717 | Change | 3.59% |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director Director | Feb 01 | Buy | 12.09 | 2,481,350 | 29,999,522 | 4,873,721 | 02/05/24 |
| Morabito Christopher | Chief Medical Office.. Chief Medical Officer | Jan 26 | Sell | 11.08 | 10,000 | 110,800 | 01/30/24 | |
| Morabito Christopher | Chief Medical Office.. Chief Medical Officer | Jan 26 | Option | 3.87 | 10,000 | 38,700 | 9,200 | 01/30/24 |
| PERCEPTIVE ADVISORS LLC | Director Director | Dec 19 | Buy | 11.01 | 908,265 | 9,999,998 | 1,038,309 | 12/21/22 |